A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF SATRALIZUMAB AS MONOTHERAPY OR IN ADDITION TO BASELINE THERAPY IN PATIENTS WITH MYELIN OLIGODENDROCYTE

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (mogad)
  • Age: Between 12 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Able to provide written informed consent form. If participant is under 18 years old, they must be able to provide assent and their parent/legal guardian must be able to provide consent
    2. Confirmed diagnosis of MOGAD meeting the f

You may not be eligible for this study if the following are true:

    1. Presence of AQP4-IgG in the serum
    2. History of encephalitis unrelated to MOGAD
    3. Dawson’s finger-type T2/FLAIR hyperintense lesions
    4. Participants who have experienced a MOGAD relapse within 12 weeks prior to


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.